topoisomerase ii inhibitor

Razoxane is used as an antimitotic agent with immunosuppressive properties.

Topoisomerase II inhibitor 13 inhibits topoisomerase II (Topo II) that shows strong anti-proliferation activity against HL-60/MX2 cancer cells derived from HL-60 against Topo II toxicity.

TopoisomeraseII Inhibitor 20 TFA is a potent inhibitor of topoisomerase II with an IC50 of 0.98 µM. It can induce cell apoptosis and exhibits broad-spectrum anticancer activity.

TopoisomeraseII inhibitor 17 (compound 4c) is a thiazolopyrimidine-based inhibitor of Topoisomerase II with an IC50 of 0.23 μM. This compound significantly disrupts the cell cycle and induces apoptosis.

Topoisomerase II inhibitor 19 (compound 5h) is a DNA intercalator and a topoisomerase II inhibitor with an IC50 of 0.34 μM. It induces damage in ctDNA.

TopoisomeraseII inhibitor 20 (Compound 3e) is a potent inhibitor of Topoisomerase II, with an IC50 of 0.98 µM. It can induce apoptosis and possesses broad-spectrum anticancer activity.

TopoisomeraseII inhibitor 23 is a potent inhibitor of topoisomerase II (topoisomeraseII) with an IC50 value of 0.94 μM. Compared to doxorubicin (IC50 of 3.08 μM), it exhibits high selectivity and superior cytotoxic effects in MCF-7, HepG2, and HCT116 cells. This compound induces cell cycle arrest at the G1 phase, leading to the inhibition of cell proliferation. It also promotes apoptosis (apoptosis) by upregulating the pro-apoptotic protein Bax and downregulating the anti-apoptotic protein Bcl-2.

Topoisomerase II inhibitor 8 (compound 22) is a potent inhibitor of topoisomerase II (IC50 = 0.52 μM) [1] and exhibits strong anti-proliferative activities, arresting the cell cycle at the G2/M phase.

Topoisomerase II inhibitor 6 (Compound 5), a tryptanthrin derivative, is a potent and selective topoisomerase II inhibitor that blocks the CCRF-CEM cell cycle in the G2 phase and induces DNA double-strand breaks (DSB). It exhibits antiproliferative activity on various tumor cell lines and has potential for cancer research [1].

Topoisomerase II inhibitor 3 (Compound 6 h) is an acridone derivative acting as a Type II DNA topoisomerase (topo II) inhibitor. It specifically targets topo IIα/β subtypes, with IC50 values of 0.17 μM for topo IIα and 0.23 μM for topo IIβ, causing significant DNA damage and inducing apoptosis by triggering the loss of mitochondrial membrane potential [1].

Topoisomerase II inhibitor 4 (compound E17) is a potent topoisomerase II inhibitor with antitumor effects, blocking the cell cycle in the G2/M phase, inhibiting cancer cell proliferation, and exhibiting cytotoxicity.

Topoisomerase II inhibitor 5 (Compound E24) is a DNA topoisomerase II inhibitor with anticancer properties.

Topoisomerase II inhibitor 9 is a Topo II inhibitor (IC50: 0.97 μM) and DNA embedding agent (IC50: 43.51 μM) that blocks the Hep G-2 cell cycle in the G2/M phase and induces apoptosis.

DNA topoisomerase II inhibitor 1 is a potent inhibitor of DNA topoisomerase II that arrests the cell cycle in sub-G1 phase and induces apoptosis with anti-value-added effects.

Topoisomerase II inhibitor 10 is a potent inhibitor of topoisomerase II (IC50: 7.45 μM). Topoisomerase II inhibitor 10 was able to arrest the cell cycle of HepG-2 cells in the G2-M phase and induce apoptosis.

Topoisomerase II inhibitor 11 (compound 3d) is a potent inhibitor of Topoisomerase II (IC50: 2.89 μM), inhibiting cell proliferation and inducing apoptosis by arresting the cell cycle in the G2/M phase.

Topoisomerase II inhibitor 7, a potent inhibitor of the topoisomerase II alpha subtype, exhibits an IC50 of 3.19 μM. It effectively induces cell cycle arrest and apoptosis.

Topoisomerase II inhibitor 15 (compound 2g) is a potent inducer of apoptosis, demonstrating high selectivity for head and neck tumors [1].

Topoisomerase II inhibitor 18 (Compound IV), a Quinoxaline derivative, exhibits an IC 50 of 7.5 μM in inhibiting topoisomerase II. It impedes PC-3 cell proliferation, arrests the cell cycle at the S phase, and induces apoptosis. Moreover, this compound demonstrates substantial antitumor activity against cancer [1].

TopoisomeraseI/II inhibitor 6 (compound 3i) acts as an effective inhibitor of topoisomerase I and II, with IC50 values of 4.77 µM and 15 µM, respectively. Additionally, it exhibits antiproliferative activity against the human melanoma cell line LOX IMVI, demonstrating IC50 values of 26.7 µM and 25.4 µM.

Compound 5h (Topoisomerase I/II inhibitor 7) is a Topoisomerase I/II inhibitor.

Topoisomerase I/II inhibitor 2 (compound 1a) is a DNA topoisomerase I/II dual inhibitor that significantly reduces xenograft tumor growth in a mouse model, indicating its potential use in treating liver cancer. It is a potent topoisomerase inhibitor with IC50 values of 6.83 μM and 9.82 μM for LM9 cells and Huh7 cells [1].

Type II topoisomerase inhibitor 1 is a potent and selective inhibitor of E. coli DNA gyrase with an IC50 value of 1.7 nM and forms hydrogen bonds with the Asp73 residue. It inhibits topoisomerase IV activity with an IC50 value of 0.98 μM and is applicable in the antibacterial area [1] [2].

Topoisomerase I/II inhibitor 3 (compound 7) is a potent dual inhibitor of topoisomerase I (Topo I) and II (Topo II) that inhibits the PI3K/Akt/mTOR signaling pathway, subsequently inhibiting cell proliferation, invasion, and migration, and inducing apoptosis. This compound has research value in liver cancer.